Section Arrow
Quote
IMCR.NASDAQ
- Immunocore Holdings plc
Quotes are at least 15-min delayed:2025/03/28 00:17 EDT
Last
 30.13
+0.66 (+2.24%)
Day High 
30.34 
Prev. Close
29.47 
1-M High
31.64 
Volume 
555.27K 
Bid
28.91
Ask
30.5
Day Low
28.92 
Open
29.03 
1-M Low
27.19 
Market Cap 
1.48B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 29.29 
20-SMA 29.36 
50-SMA 29.99 
52-W High 66 
52-W Low 27.19 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.02/-1.74
Enterprise Value
1.91B
Balance Sheet
Book Value Per Share
7.20
Cash Flow
Cash Flow Yield
0.02
Income Statement
Total Revenue
310.20M
Operating Revenue Per Share
4.68
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed：2025/03/28 00:17 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.